Cytomegalovirus immune globulin - Shanxi Kangbao Biological Product

Drug Profile

Cytomegalovirus immune globulin - Shanxi Kangbao Biological Product

Latest Information Update: 15 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanxi Kangbao Biological Product
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cytomegalovirus infections

Most Recent Events

  • 15 Jan 2016 Early research in Cytomegalovirus infections (Prevention) in China (IV) prior to January 2016 (Shanxi Kangbao Biological Product pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top